Mechanisms of Ibrutinib Resistance Identified in Chronic Leukemia

May 29, 2014
Mechanism of Ibrutinib Resistance Identified in Chronic Leukemia John Byrd
  • Ibrutinib is a new and highly effective drug for chronic lymphocytic leukemia (CLL), a cancer of the blood that affects 15,700 people annually and has no cure.
  • In some people, CLL becomes resistant to ibrutinib, rendering the drug ineffective.
  • This study describes two mechanisms of ibrutinib resistance in CLL.
  • The findings could lead to strategies to prevent or reverse this resistance.

COLUMBUS, Ohio – A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia (CLL).

The study was published in the New England Journal of Medicine​ and led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). It identifies gene mutations that cause ibrutinib resistance in CLL patients.

"Knowledge of these mutations is the first step in the development of drugs or drug combinations that might prevent or treat ibrutinib-resistant CLL," says co-principal investigator John C. Byrd, MD, director, division of hematology, and professor of medicine, of medicinal chemistry and of veterinary biosciences at Ohio State.

"Importantly, we saw none of these mutations in patients before they used ibrutinib," says Amy Johnson, PhD, associate professor of medicine in the division of hematology, an OSUCCC – James researcher and a co-principal investigator of the study.

Ibrutinib (Imbruvica®) works by permanently binding with a protein called Bruton's tyrosine kinase (BTK), a molecule that CLL cells need to grow and proliferate. BTK is one in a chain of proteins that relays growth signals from the surface of CLL cells to genes in the cell nucleus. By blocking BTK, ibrutinib halts the flow of these growth signals, and the CLL cells die (download an illustration).

The researchers found, however, that CLL cells can develop a mutation in BTK itself that weakens the ability of ibrutinib to bind with the protein. This leaves the drug less able to block BTK’s action. The researchers also found two mutations in a protein that comes after BTK in the signaling pathway. Those mutations allow growth signals to travel the pathway even when BTK is blocked, rendering ibrutinib ineffective.

An estimated 15,700 new cases of CLL are expected in the United States in 2014, along with 4,600 deaths from the disease, which still has no cure.

Clinical trials have shown that ibrutinib is a highly effective drug for CLL and that it causes few serious side effects. Patients with relapsed CLL have shown a 71-percent overall response rate, and another 15-20 percent achieved a partial response. The estimated progression-free survival is 75 percent at 26 months.

"At this point, few patients taking ibrutinib have relapsed," says first author Jennifer Woyach, MD, assistant professor in the division of hematology and an OSUCCC – James researcher. "But as more patients use the drug, it becomes more important to learn how resistance occurs and to have effective alternative therapies for patients who need them. And as other irreversible kinase inhibitors are developed for key signaling pathways in cancer, it will be important to learn if this is a general pattern of resistance," she says

For this study, Byrd, Woyach, Johnson and their colleagues examined samples from six CLL patients who had developed ibrutinib resistance. The samples were obtained before treatment started and after resistance developed. Key technical findings included:

  • Ibrutinib resistance is due at least in part to a cysteine-to-serine mutation in BTK at the ibrutinib binding site and to mutations in a protein called PLC gamma 2;
  • Patients with lymphocytosis, which is an increase in the number of lymphocytes in the blood, showed no evidence of the resistance mutations;
  • The risk of relapse may be greatest for cases of CLL that show greater genomic instability, such as those with deletions in chromosomes 17 and 11.

"Overall, our findings emphasize the importance of this pathway in ibrutinib’s mechanism of action in CLL," says Byrd, who holds the D. Warren Brown Designated Chair in Leukemia Research, directs the OSUCCC – James CLL Experimental Therapeutics Laboratory and co-leads the Leukemia Research Program.

Funding from Four Winds Foundation; D. Warren Brown Foundation; Mr. and Mrs. Michael Thomas; Mr. and Mrs Al Lipkin; Harry T. Mangurian Jr. Foundation; NIH/National Cancer Institute (grants CA140158, CA177292); Leukemia & Lymphoma Society; Pharmacyclics, Inc; Conquer Cancer Foundation; ASH Scholar Award; Else Kröner-Fresenius-Stiftung (2010_Kolleg24, Project 2012_A146); Virtual Helmholtz Institute (VH-VI-404, TP2) and DFG (SFB 1074 project B2) supported this research.

Other researchers involved in this study were Ta-Ming Liu, Hatice Gulcin Oze, Amy Ruppert-Stark, Ayse Selen Yilmaz, Samantha Jaglowski, Kristie A. Blum, Arletta Lozanski and Gerard Lozanski, The Ohio State University; Richard R. Furman, Weill Cornell Medical College; Marc Zapatka and Peter Lichter, German Cancer Research Center DKFZ; Ling Xue, Daniel Li, Susanne M. Steggerda, Danelle F. James, Betty Y. Chang and Joseph J. Buggy, Pharmacyclics, Inc.; Sandeep S. Dave, Duke University; Jacqueline Barrientos, Hofstra North Shore-LIJ School of Medicine; Stephan Stilgenbauer, University of Ulm, Ulm Germany; Matthias Versele, Janssen Research & Development, Beerse, Belgium.

About The OSUCCC - James

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program’s 228-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.



High quality JPEGs are available here for John C. Byrd, MD, Amy Johnson, PhD, and Jennifer Woyach, MD.

Research by Byrd and others at the OSUCCC – James contributed to the FDA’s February 2014 approval of ibrutinib for CLL. Read more.

Written by: Darrell E. Ward, Wexner Medical Center Public Affairs and Media Relations, 614-293-3737, or

Media Contact: Amanda J. Harper, Director of Media Relations, The OSUCCC–James, 614-293-3737 (central media line), 614-685-5420 (direct) or

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Prostate Cancer Androgen Receptor Activates a Different Gene Set When Bound to Antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by...

Read More

Individualizing Treatments for Multiple Myeloma

This week on Toward a Cancer-Free World, Dr. Craig Hofmeister shares how using an actual virus to help treat certain blood cancer patients may just get us even closer to a cancer-free world.

Read More

Generating New Hope Through Pelotonia-Funded Research

Pelotonia funds support cancer drug development projects at Ohio State. Here’s a brief look at a basic-science study of a targeted agent that may improve cancer-killing virus therapy, and two clinical...

Read More